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Levels of asthma control




































 Dynamic chronic illness
 Variability overtime
 Imperfect overlap between symptoms frequency and lung 
function
 Adding lung function measurement  change severity 
classification  change treatment
 Needs review and regular monitoring
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Peak expiratory flow (PEF)
 Inexpensive
 Patients can use at home
 May be helpful for patients with severe disease to monitor 
their change from baseline every day
 Not recommended for all patients with mild or moderate 
disease to use every day at home
 Effort and technique dependent
 Should not be used to make diagnosis of asthma
Lung Function Measurement
Spirometry
 Recommended to do spirometry pre- and post- use 
of an albuterol MDI to assess reversibility of airflow 
obstruction
 > 12% reversibility / increase FEV1 of 200cc is 
significant
 Obstructive pattern:  reduced FEV1/FVC ratio






 To identify reversible airway obstruction due to 
triggers
 To diagnose Exercise-induced asthma (EIA) or 
Exercise-induced bronchospasm (EIB) by measuring 
FEV1/FVC before and after exercise, then for 5-10 
minute intervals over 20-30 minutes looking for 
post-exercise bronchoconstriction
Lung Function Measurement
Goals in Asthma Control
 Achieve and maintain control of symptoms
 Prevent asthma episodes or attacks
 Minimal use of reliever medication
 No emergency visits to doctors or hospitals
 Maintain normal activity levels, including exercise
 Maintain pulmonary function as close to normal as 
possible
 Minimal (or no) adverse effects from medicine
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LAßA to ICS therapy
Kips et al, AJRCCM 2000 Pauwels 





• to control / prevent symptoms &/ attack
• long term use 
• anti-inflammations








 The most effective anti-inflammatory medications
 Improve lung function
 Decrease airway hyper-responsiveness
 Reduce symptoms
 Decrease frequency and severity of  exacerbations
 Improve Quality of  Life (QoL)
Corticosteroids
 Inhaled Corticosteroids
 Anti-inflammatory (but precise MOA not known)
 Act locally in lungs 
 Some systemic absorption
 Risks of possible growth retardation outweighed by 
benefits of controlling asthma
 Not intended to be used as rescue medication
 Efficacy takes 1-2 weeks















 Beta2-receptors are the predominant receptors in 
bronchial smooth muscle
 Stimulate ATP-cAMP  relaxation of bronchial 
smooth muscle and inhibition of release of 
mediators of immediate hypersensitivity
 Inhibits release of mast cell mediators such as 




 Salmeterol with fluticasone (Advair)
 Should only be used as an additional treatment
when patients are not adequately controlled with ICS
 Should not be used as rescue medication
 Can be used >4 yrs with a DPI
 Deaths associated with inappropriate use as only 
medication for asthma
Long-Acting Beta2-Agonists (LABA)
Inhaled Steroid + LABA
Adding LABA to BUD:
 Reduces rate of mild exacerbations







 Immediate relief (as fast as salbutamol)
 12 hours effect
 Can be combined with budesonide
 Formoterol 4.5 ug + Budesonide 100 ug
Salmeterol:
 Salmeterol 50 ug + Fluticasone propionate 100 ug or 
250 ug































 Leukotriene-mediated effects include:
 Airway edema
 Smooth muscle contraction
 Altered cellular activity associated with the inflammatory 
process
 Receptors in airway smooth muscle cells and 
macrophages and on other pro-inflammatory cells 
(including eosinophils and myeloid stem cells) and 
nasal mucosa
Leukotriene receptor antagonists
 No good long-term studies in pediatrics
 Montelukast as young as 2 yr dose 1 x 4 –5 mg; 
zarfirlukast age 7 yr dose 2 x 10 mg
 Alternate, but not preferred medication in persistent 
asthma and as addition to ICS
 Showed a statistically significant, but modest 





 Narrow therapeutic index, maintain 5-20 mcg/mL
 Sustained release Theophylline (SRT) 5- 10 mcg/mL
 Variability in clearance leads to reach a therapeutic dose
 Mechanism of action
 Smooth muscle relaxation (bronchodilation)
 Suppression of the response of the airways to stimuli
 Increase force of contraction of diaphragmatic muscles





 Inhibits release of mediators from mast cells 
(degranulation) after specific antigens exposure
 Blocks Ca2+ ions from entering the mast cell
 Safe for pediatrics (including infants)
 Should be started 2-4 weeks before allergy season
 Can be used before exercise (not as good as ICS)













































Wheeze free and well for three 
months:
 Oral steroid 
1 mg/kgBW/month, then
 SRT 









 Coordination & support
2. Asses & monitor asthma (PEFR)
3. Environmental control measures
4. Medication plan (accommodate variability 
among & within patients)
5. Plan for acute management
6. Regular follow-up care
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PELATIHAN
Internasional
1. Clinical Training for Consultant on Acute Respiratory Infections. 
Bangkok, 1991. 
2. Pediatric Pulmonology, Vrije Universiteit Amsterdam. Amsterdam, 
1995 
3. Workshop on Technology Assesment and Management Tools. 
Thailand, 1998 




1. Workshop of Building Linkages Socialization of ICDC project in the West Region. 
Palembang,2000 
2. Workshop on Curriculum Development and Revision. FK Undip Semarang, 2001 
3. Workshop on Evidence Based Medicine. FKUI-FK Undip Semarang, 2001 
4. Advanced Pediatric Resuscitation Course. PP IDAI. Semarang, 2002 
5. TOT Pembuatan OSCA untuk Uji Kompetensi Tenaga Kesehatan. Semarang, 2003 
6. Diagnostic Test for Respiratory Syncytial Virus. WHO-Unpad. Bandung, J2003 
7. Pentaloka Penulisan Artikel Ilmiah Kesehatan. Depkes RI. Semarang, 2003 
8. National workshop on Integrated Pharmacotherapy Teaching for Medical Undergraduate. 2004 
9. Quality Assurance for Medical Education. FK Undip Semarang, 2004 
10. Pelatihan Vaksinologi PP IDAI-IDAI Jateng. Semarang, 2006 
11. Komite Nasional Etik Penelitian Kesehatan (KNEPK) dengan Komisi-Komisi Etik Penelitian
Kesehatan (KEPK). Semarang, 2006 
12. Lokakarya Penyusunan Kurikulum Berbasis Kompetensi. FK Undip. Semarang, 2006 
13. Pelatihan tutor BBDM. FK UNDIP. Semarang, 2006 
14. Lokakarya Nasional Kejadian Ikutan Pasca Imunisasi (KIPI). Jakarta, 2007 
15. Lokakarya Contributing Editor Paediatrica Indonesiana., Jakarta 2007 
